在III-IV阶段的复发性或耐药性阴茎状细胞癌中,达尔利马布加尼拉帕里布的第二阶段研究
Firas Hatoum1, Gabriel Roman Souza1, Jeff Johnson1
1Genitourinary Oncology Department, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Future oncology (London, England)
|October 30, 2025
概括
这项试验研究了将PARP抑制剂尼拉帕里布与PD-1抑制剂德利利马布结合用于晚期阴茎平细胞癌. 这种组合显示出作为耐火病例新型治疗策略的潜力.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 生殖尿道癌症 生殖尿道癌症
背景情况:
- 阴茎状细胞癌 (PSCC) 的管理具有挑战性,选择有限.
- 临床前数据表明,结合PD-1和PARP抑制剂可以产生协同作用的抗瘤效应.
研究的目的:
- 评估尼拉帕里布加达利利马布在患有复发性或耐火性III-IV期PSCC的患者中的疗效和安全性.
- 确定客观响应率 (ORR) 作为主要终点.
主要方法:
- 第二阶段临床试验,招募患有晚期PSCC的患者.
- 与尼拉巴里布 (PARP 抑制剂) 和达利利马布 (PD-1 抑制剂) 的联合治疗.
- 主要终点:ORR通过iRECIST;次要终点:PFS,OS,安全.
主要成果:
- 该研究目前正在两阶段招募患者.
- 第一个阶段将招收15名患者,如果ORR超过13%,则将扩展到10名.
结论:
- 这种组合疗法可能为先进的,耐火的PSCC提供一种新的治疗方法.
- 进一步的结果正在等待患者招募和数据收集.
关键词:
阴茎的新生体.复合 ((ADP-ribose) 聚合酶抑制剂的使用组合 组合 组合 组合 组合提供了可靠的服务.药物治疗是药物治疗.免疫检查点抑制剂 免疫检查点抑制剂尼拉帕里布里布里布.二期临床试验的临床试验.更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.8K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
